Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the activity of larotrectinib (Vitrakvi) in patients with TRK fusion–positive non–small cell lung cancer.
Alexander E. Drilon, MD
Advertisement
Articles by Alexander E. Drilon, MD
Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses rare drivers in non–small cell lung cancer (NSCLC).
Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses the adoption of next-generation sequencing (NGS) in lung cancer.
Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Dr. Drilon on Tepotinib and Gefitinib in MET+ EGFR-Mutant NSCLCPublished: November 15th 2018 | Updated:
Dr. Drilon Discusses the Adoption of NGS in Lung CancerPublished: February 8th 2019 | Updated:
- Dr. Drilon on Rare Drivers in NSCLC
Published: February 15th 2019 | Updated:
Dr. Drilon on Activity of Larotrectinib in TRK Fusion-Positive NSCLCPublished: April 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5